VERÖFFENTLICHUNGEN (AUSWAHL)

Lehrbuch Gynäkologische Onkologie 2019
5. Auflage
Springer Verlag
 

 

 

 

 

 

 

Petru, E., Berger, M., Zeller, J., Kaufmann, M.:
In vitro evaluation of an estradiol-linked nitrosourea in mammary carcinomas of mouse, rat, and man.
Eur. J. Cancer Clin. Oncol. 24 (1988) 1027-1032

Petru, E., Tamussino, K., Lahousen, M., Winter, R., Pickel, H., Haas, J.:
Pelvic and paraaortic lymphocysts after radical surgery because of cervical and ovarian cancer.
Am. J. Obstet. Gynecol. 161 (1989) 937-941

Petru, E., Lahousen, M., Tamussino, K., Pickel, H., Stranzl, H., Stettner, H., Winter, R.:
Lymphadenectomy in stage I ovarian cancer.
Am. J. Obstet. Gynecol. 170 (1994) 656-662

Petru, E., Moinfar, F., Graf, S.:Regulation of the E2F family – A further step in understanding ovarian cancer biology.
Cancer Biol. & Ther. 5 (2006) 777-778

 Petru, E., Sevin, B.U., Perras, J., Boike, G., Ramos, R., Nguyen, H., Averette, H.:
Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence.
Gynecol. Oncol. 38 (1990) 155-160

 Petru, E., Angleitner-Boubenizek, L., Reinthaller, A., Deibl, M., Zeimet, A., Volgger, B., Stempfl, A., Marth, C.:
Combined PEG liposomal doxorubicin and germcitabine are active and have
acceptable toxicity in patients with platinum-refractory and –resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study.
Gynecol. Oncol. 102 (2006) 226-229

Petru, E., Pickel, H., Heydarfadai, M., Lahousen, M., Haas, J., Schaider, H.,
Tamussino, K.:
Nongenital cancers metastatic to the ovary.
Gynecol. Oncol. 44 (1992) 83-86

Petru, E., Sevin, B.U., Haas, J., Ramos, R., Perras, J.:
A correlation of cell cycle perturbations with chemosensitivity in human ovarian
cancer cells exposed to cytotoxic drugs in vitro.
Gynecol. Oncol. 58 (1995) 48-57

 Bader, A., Schlembach, D., Tamussino, K., Petru, E.:
Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy.
Lancet Oncol. 8 (2007) 79-81

Greimel, E., Daghofer, F., Petru, E.:
Prospective assessment of quality of life in long-term ovarian cancer survivors.
Int. J. Cancer 128 (2011) 3005-3011

Pristauz, G., Petru, E., Stacher, E., Geigl, J., Schwarzbraun, T., Tsybrovskyy, O., Winter, R., Moinfar, F.:
Androgen receptor expression in breast cancer patients tested for BRCA 1 and BRCA 2 mutations.
Histopathology 57 (2010) 877-884

Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Reed, N., Gebski, V., Pujade-Lauraine, E., Lord, S., Simes, R., Friedlander, M.:
Carboplatin-paclitaxel-induced leucopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Br. J. Cancer 105 (2011) 360-365

Kurtz, J., Kaminsky, M., Floquet, A., Veillard, A., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N., Scambia, G., Varsellona, N., Brown, C., Pujade-Lauraine, E.:
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: A Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Ann. Oncol. 22 (2011) 2417-2423

Zeimet, A., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Azim, S., Müller-Holzner, E., Ben-Arie, A., Van Kempen, L., Petru, E.,  Jahn, S., Geels, Y., Massuger, L., Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., Oppelt, P., Stroh-Weigert, M., Reinthaller, A., Mariani, A., Hackl, W., Netzer, M., Schirmer, U., Vergote, I., Altevogt, P., Marth, C., Fogel, M.:
L1CAM in early-stage type I endometrial cancer: Results of a large multicenter evaluation.
J. Natl. Cancer Inst. 105 (2013) 1142-1150

Heitzer, E., Auer, M., Hoffmann, E., Pichler, M., Gasch, C., Ulz, P., Lax, S., Waldispuehl-Geigl, J., Mauermann, O., Mohan, S., Pristauz, G., Lackner, C., Höfler, G., Eisner, F., Petru, E., Sill, H., Samonigg, H., Pantel, K., Riethdorf, S., Bauernhofer, T., Geigl, J., Speicher, M.:
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int. J. Cancer 133 (2013) 346-356